Donna Oneal
Critical Care Medicine · Uniontown, PANPI 1902273055
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Among critical care medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Boehringer Ingelheim$751
- Grifols USA, LLC$532
- AbbVie$470
- Verona Pharma, Inc.$373
- plus $2K from 12 others
What the payments were for
- Food & beverage$6,61299%
- Education$871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $1,537 |
| GSK | 58 | $1,156 |
| Boehringer Ingelheim | 30 | $751 |
| Grifols USA, LLC | 26 | $532 |
| AbbVie | 5 | $470 |
| Verona Pharma, Inc. | 10 | $373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $347 |
| Sanofi | 13 | $311 |
| Amgen | 13 | $293 |
| E.r. Squibb & Sons, L.L.C. | 2 | $248 |
| Regeneron Healthcare Solutions, Inc. | 8 | $224 |
| Electromed, Inc. | 8 | $141 |
| Pfizer | 1 | $98 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Pulmonx Corporation | 1 | $67 |
| Mylan Specialty L.p. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,699 in reported general payments places this provider in the 90th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 492 | $360,906 |
| Spiriva RespimatTiotropium Bromide | 250 | $148,224 |
| GlassiaAlpha-1-Proteinase Inhibitor | 14 | $104,075 |
| NucalaMepolizumab | 14 | $79,369 |
| Breo ElliptaFluticasone/Vilanterol | 175 | $74,791 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 108 | $73,798 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 101 | $58,055 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 74 | $44,100 |
| Incruse ElliptaUmeclidinium Bromide | 86 | $39,009 |
| SymbicortBudesonide/Formoterol Fumarate | 76 | $27,222 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 769 | $24,597 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 120 | $22,569 |
| Advair HfaFluticasone Propion/Salmeterol | 55 | $21,199 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 90 | $17,182 |
| Spiriva HandihalerTiotropium Bromide | 14 | $11,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,156 | $612,129868 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $751 | $198,618337 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,537 | $109,325204 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $347 | $104,07514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Uniontown
- Alok BhattUniontown$4K
- Briana DisilvioPittsburgh$204K
- Meilin YoungPittsburgh$182K
- Robert KruklitisAllentown$148K
- Lisa RathmanLancaster$86K
- Kees PoldermanPittsburgh$85K
- Pavan ThanguduHarrisburg$78K
- David DibardinoPhiladelphia$63K
- Harold PalevskyPhiladelphia$55K
- Steven KawutPhiladelphia$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.